A687V EZH2 is a driver of histone H3 lysine 27 (H3K27) hypertrimethylation.
Saved in:
| Title: | A687V EZH2 is a driver of histone H3 lysine 27 (H3K27) hypertrimethylation. |
|---|---|
| Authors: | Ott HM; Cancer Epigenetics Discovery Performance Unit, Cancer Research, Oncology R&D, GlaxoSmithKline, Collegeville, Pennsylvania., Graves AP; Platform Technology and Science, GlaxoSmithKline, Collegeville, Pennsylvania., Pappalardi MB; Cancer Epigenetics Discovery Performance Unit, Cancer Research, Oncology R&D, GlaxoSmithKline, Collegeville, Pennsylvania., Huddleston M; Platform Technology and Science, GlaxoSmithKline, Collegeville, Pennsylvania., Halsey WS; Platform Technology and Science, GlaxoSmithKline, Collegeville, Pennsylvania., Hughes AM; Platform Technology and Science, GlaxoSmithKline, Collegeville, Pennsylvania., Groy A; Cancer Epigenetics Discovery Performance Unit, Cancer Research, Oncology R&D, GlaxoSmithKline, Collegeville, Pennsylvania., Dul E; Platform Technology and Science, GlaxoSmithKline, Collegeville, Pennsylvania., Jiang Y; Platform Technology and Science, GlaxoSmithKline, Collegeville, Pennsylvania., Bai Y; Molecular Medicine Unit, Cancer Research, Oncology R&D, GlaxoSmithKline, Collegeville, Pennsylvania., Annan R; Platform Technology and Science, GlaxoSmithKline, Collegeville, Pennsylvania., Verma SK; Cancer Epigenetics Discovery Performance Unit, Cancer Research, Oncology R&D, GlaxoSmithKline, Collegeville, Pennsylvania., Knight SD; Cancer Epigenetics Discovery Performance Unit, Cancer Research, Oncology R&D, GlaxoSmithKline, Collegeville, Pennsylvania., Kruger RG; Cancer Epigenetics Discovery Performance Unit, Cancer Research, Oncology R&D, GlaxoSmithKline, Collegeville, Pennsylvania., Dhanak D; Cancer Epigenetics Discovery Performance Unit, Cancer Research, Oncology R&D, GlaxoSmithKline, Collegeville, Pennsylvania., Schwartz B; Platform Technology and Science, GlaxoSmithKline, Collegeville, Pennsylvania., Tummino PJ; Cancer Epigenetics Discovery Performance Unit, Cancer Research, Oncology R&D, GlaxoSmithKline, Collegeville, Pennsylvania., Creasy CL; Cancer Epigenetics Discovery Performance Unit, Cancer Research, Oncology R&D, GlaxoSmithKline, Collegeville, Pennsylvania. Molecular Medicine Unit, Cancer Research, Oncology R&D, GlaxoSmithKline, Collegeville, Pennsylvania., McCabe MT; Cancer Epigenetics Discovery Performance Unit, Cancer Research, Oncology R&D, GlaxoSmithKline, Collegeville, Pennsylvania. michael.t.mccabe@gsk.com. |
| Source: | Molecular cancer therapeutics [Mol Cancer Ther] 2014 Dec; Vol. 13 (12), pp. 3062-73. Date of Electronic Publication: 2014 Sep 24. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: American Association for Cancer Research, Inc Country of Publication: United States NLM ID: 101132535 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1538-8514 (Electronic) Linking ISSN: 15357163 NLM ISO Abbreviation: Mol Cancer Ther Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
